"10.1371_journal.pone.0104175","plos one","2014-08-22T00:00:00Z","Lenard A Adler; David B Clemow; David W Williams; Todd M Durell","Departments of Psychiatry and Child and Adolescent Psychiatry, New York University, New York, New York, United States of America; Lilly USA, LLC, Indianapolis, Indiana, United States of America; inVentiv Health Clinical, Indianapolis, Indiana, United States of America","Conceived and designed the experiments: LAA DWW TMD. Performed the experiments: LAA. Analyzed the data: LAA DBC DWW TMD. Contributed reagents/materials/analysis tools: DBC DWW TMD. Wrote the paper: LAA DBC DWW TMD.","The authors have read the journal’s policy and have the following conflicts: Dr. Adler has received research funding from Bristol-Myers Squibb, Chelsea Therapeutics, Eli Lilly and Company and/or one of its subsidiaries, National Institute of Drug Abuse, Pfizer, Shire; served on advisory boards or as a consultant for Astra Zeneca Pharmaceuticals, Eli Lilly and Company and/or one of its subsidiaries, i3 Research, Major League Baseball, Mindsite, Shire; served as a consultant for Epi-Q, INC Research, Otsuka Pharmaceuticals, and United Biosource; and has received royalty payments (as inventor) from NYU for license of adult ADHD scales and training materials. Drs. Clemow and Durell are full-time employees and minor shareholders of Eli Lilly and Company and/or one of its subsidiaries (Eli Lilly USA, LLC). Mr. Williams is a full-time employee of PharmaNet/i3 (vendor provider of Eli Lilly), and he is a former employee of Eli Lilly. Eli Lilly USA, LLC was the commercial source that funded all aspects of the study described in this manuscript, and Eli Lilly is the patent holder and marketing sponsor of Strattera (atomoxetine). This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials, and there are no restrictions on sharing of data and/or materials associated with this study.","2014","08","Lenard A Adler","LAA",4,TRUE,3,1,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
